Previous 10 | Next 10 |
DUBLIN , July 29, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that it has entered into a settlement and license agreement (the agreement) with Amneal Pharmaceuticals LLC (Amneal) to resolve Amneal's inter partes review (IPR) petition challenging U.S. Pat...
Alkermes plc (ALKS) Q2 2019 Results Earnings Conference Call July 25, 2019, 08:00 AM ET Company Participants Sandra Coombs - Vice President, Investor Relations James Frates - Senior Vice President and Chief Financial Officer Craig Hopkinson - Chief Medical Officer and Senior Vice...
The following slide deck was published by Alkermes plc in conjunction with their 2019 Q2 earnings Read more ...
Alkermes plc (NASDAQ: ALKS ) Q2 result s ($M): Revenues: 279.9 (-8.1%); Vivitrol: 88.2 (+15.7%); Aristrada: 48.4 (+44.0%); license revenue: 1.0 (-97.9%). More news on: Alkermes plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Alkermes (NASDAQ: ALKS ): Q2 Non-GAAP EPS of $0.09 beats by $0.21 ; GAAP EPS of -$0.27 beats by $0.15 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more ...
-- Second Quarter Revenues of $279.9 Million , Primarily Driven by Approximately 24% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.27 and Non-GAAP Net Income per Share of $0.09 -- DUBLIN , Ju...
DUBLIN , July 18, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Thursday, July 25, 2019 , to discuss the company's second quarter 2019 financial results. Management will also provide an ...
Akero Therapeutics (NASDAQ: AKRO ) initiated with Buy rating and $28 (41% upside) price target at Jefferies. Shares down a fraction premarket. More news on: Akero Therapeutics, Inc., Atreca, Inc., Personalis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
— Following Pre-NDA Meeting With FDA, Company Plans to Submit New Drug Application for Schizophrenia and Bipolar I Disorder Indications in the Fourth Quarter of 2019 — DUBLIN , July 15, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today provided an update on i...
Central nervous system ((CNS)) disorder drug development is a particularly difficult branch of biopharma drug development. Intra-Cellular Therapies (ITCI) has experienced this firsthand, with inconsistent late-stage results for ITI-007 (Lumateperone), a promising therapy for certain CNS disord...
News, Short Squeeze, Breakout and More Instantly...
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Alkermes plc Reports Second Quarter 2024 Financial Results PR Newswire — Second Quarter Revenues of $399.1 Million — — Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income from C...
2024-07-22 10:45:03 ET Enbridge Inc (ENB) ENB is trading UP for the last 5 days, and it at trading at $36.59 with volume of 731,965 and a one day change of $0.05 (0.14%). Enbridge Inc has a 52-week low of 31.03 and a 52-week high of $38.36. The business's 50-day moving average price...